Qlaris Bio Appoints Robert Warner to Board of Directors

DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage biotechnology company focused on developing first-in-class therapies for glaucoma, today announced the appointment of Robert Warner to its board of directors. Mr. Warner’s appointment comes at a key time for Qlaris as the company continues to advance its lead development program, QLS‑111, through late-stage clinical trials as a novel therapeutic agent for the treatment of glaucoma. Mr. Warner is an experienced life sciences exec